Latest From FibroGen Inc.
Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.
Keeping Track: A Novel Approval For Fluorodopa F 18, A Tentative Approval For Vumerity, And A Missed Goal Date For Zilretta
The latest drug development news and highlights from our US FDA Performance Tracker.
The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.
AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Hepatic (Liver)
- Musculoskeletal & Connective Tissue Disorders
- Renal System
- North America
- Parent & Subsidiaries
- FibroGen Inc.
- Senior Management
James A Schoeneck, Interim CEO
Pat Cotroneo, VP, Fin. & CFO
David M Dimmick, MD, VP, Quality
R. Wayne Frost, VP, RA
Elias Kouchakji, MD, VP, Clinical Dev and Drug Safety
AI Lin, MD, PhD, VP, Drug Dev.
Peony K Yu, CMO
- Contact Info
Phone: (415) 978-1200
409 Illinois St.
San Francisco, CA 94158
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.